New KRAS Inhibitor Improves PFS in NSCLC Harboring KRASG12C Mutation

A second drug has demonstrated efficacy against the once “undruggable” KRAS^G12C mutation. Based on the data so far, the new drug, adagrasib (Mirati), appears likely to join sotorasib (Lumakras, Amgen) as an option for KRAS^G12C-mutated non-small cell lung cancer (NSCLC). Sotorasib was approved about one year ago for this indication.

For KRAS^G12C-mutated NSCLC, adagrasib, like sotorasib, demonstrated efficacy in the second-line treatment. The data were drawn from the phase 2 portion